Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

mplied discussions regarding the potential development and marketing of potential future respiratory products, regarding potential future launches of indacaterol, or regarding potential future revenues from indacaterol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will successfully develop or bring to market any additional respiratory products.  Nor can there be any guarantee that indacaterol will be launched in any particular countries, or at any particular time.  Neither can there be any guarantee that indacaterol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding indacaterol could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including unexpected reimbursement difficulties or delays; competition in general; government, industry and general public pricing pressures; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015 Creekridge Capital, ... of its sales channels by adding two new sales ... as a Regional Sales Manager and Stefanie Stark ... Mr. Puma comes to Creekridge with over 20 ... his role at Creekridge, Mr. Puma will be responsible ...
(Date:6/3/2015)... 2015  The International Confederation of Midwives (ICM) has ... as a standard for midwives trained to ICM,s competency ... in consultation with ICM experts. Direct Relief will provide ... countries. As many as one in 30 ... or childbirth.  Skilled birth attendants such as midwives offer ...
(Date:6/3/2015)... 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... agreement with AbbVie (NYSE: ABBV ) to develop ... Halozyme,s ENHANZE ™ platform. ... receive an initial $23 million payment, followed by ... of up to nine collaboration targets. These payments ...
Breaking Medicine Technology:Creekridge Capital Strengthens Sales Team 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3
... Patient Record Sharing , and Secure ... Among Physicians , DAYTON, Ohio, Oct. 29 ... (HSI) announce an effort to create virtual teams that connect primary ... care of patients, improving the quality and safety of care while ...
... IRVINE, Calif., Oct. 29 PRO-DEX, INC. (Nasdaq: PDEX ... quarter ending September 30, 2009. In addition, Pro-Dex announced ... renewed, a new marketing director has been hired, a product ... shipments have been made of a newly developed product. , ...
Cached Medicine Technology:Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 2Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 3Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10
(Date:6/3/2015)... June 03, 2015 Visual BI ... solutions, today announced the launch of the second ... for SAP® BusinessObjects™ Design Studio. The Design Studio ... capabilities and advanced functionalities into their dashboarding projects. ... suite, Visual BI is adding key components for ...
(Date:6/3/2015)... The panel of independent experts has spent ... short-listed for the awards presented tonight at TU-Automotive Detroit ... but the best-of-the-best can now be revealed as: , ... Volvo swept rivals aside by taking the coveted Car ... from our panel of expert judges., Stand out comments ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
(Date:6/3/2015)... 03, 2015 For the fourth time in ... ), a full-service advertising agency, has been honored by a ... Commerce. , MCA has been selected as a Semi-Finalist for ... will be honored at a luncheon sponsored by Adcock Financial ... Museum of Art. , “This luncheon will include important information ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Sitting at ... cause discomfort in the back, neck, shoulders and/or wrists. ... musculoskeletal injuries. In addition, recent research links sitting for ... of chronic diseases. Fortunately, three inventors from Oakville, Ontario, ... at a desk. , They have developed a prototype ...
Breaking Medicine News(10 mins):Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 2Health News:My Classified Ads Has Been Selected as a Semi-Finalist for the 2015 ‘Small Business of the Year’ Awards 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2
... Medical Center has just enrolled the first U.S. patient in ... certain kinds of melanoma, a deadly skin cancer that in ... than blocking or killing all rapidly dividing cells, whether malignant ... new class of agents that have been designed to sabotage ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... 30 (HealthDay News) -- Early assessment of rheumatoid arthritis ... the likelihood of disease remission without having to take ... Although DMARDs are considered effective in treating rheumatoid ... been linked to uncommon but serious side effects. ...
... their employer, or through an employed family member,s dependent coverage. ... to a new policy brief from the UCLA Center for ... California Health Interview Survey (CHIS), the brief,s authors found that ... with at least one employed family member or 5.7 ...
... of more than 2 million mammogram screenings performed on nearly ... time show a direct link between reduced hormone therapy and ... invasive breast cancer. The researchers saw such a striking decrease, ... promote breast tumor growth. The declines occurred in ...
... system for Wilson,s disease (WD) provides good diagnostic accuracy ... in children with mild liver disease. In asymptomatic children, ... suggestive of WD, however the penicillamine challenge test (PCT) ... subset. Results of the study appear in the December ...
Cached Medicine News:Health News:International clinical trial tests targeted drug for melanoma 2Health News:Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis 2Health News:5.7 million Californians lack access to job-based coverage 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 2Health News:Drop in breast cancer rates directly tied to reduced hormone therapy 3Health News:Scoring system is 93 percent accurate for diagnosing Wilson's disease in pediatric patients 2